References
1.
Kuratsu J, Ushio Y: Epidemiological study of primary intracranial tumors in childhood. A population-based survey in Kumamoto Prefecture, Japan. Pediatr Neurosurg 1996;25:240–246.
2.
Jane JA Jr, Laws ER: Craniopharyngioma. Pituitary 2006;9:323–326.
3.
Harwood-Nash DC: Neuroimaging of childhood craniopharyngioma. Pediatr Neurosurg 1994;21(suppl 1):2–10.
4.
Kawamata T, Kubo O, Kamikawa S, et al: Ectopic clival craniopharyngioma. Acta Neurochir (Wien) 2002;144:1221–1224.
5.
Shimada M, Tsugane R, Shibuya N, Sato O: Craniopharyngioma with extension into the cerebellopontine angle. Case report. Tokai J Exp Clin Med 1989;14:113–116.
6.
Aquilina K, O’Brien DF, Fareel MA, Bolger C: Primary cerebellopontine angle craniopharyngioma in a patient with Gardner syndrome. J Neurosurg 2006;105:330–333.
7.
Losner RR, Glastonbury C, Apfelbaum RI: Retroclival craniopharyngioma. Case illustration. J Neurosurg 2001;94:539.
8.
Gokalp HZ, Egemen N, Ildan F, Bacaci K: Craniopharyngioma of the posterior fossa. Neurosurgery 1991;29:446–448.
9.
Tomita S, Mendoza ND, Symon L: Recurrent craniopharyngioma in the posterior fossa. Br J Neurosurg 1992;6:587–590.
10.
Bashir EM, Lewis PD, Edwards MR: Posterior fossa craniopharyngioma. Br J Neurosurg 1996;10:613–615.
11.
Mortini P, Loza M, Pozzobon G, et al: Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series. J Neurosurg 2011;114:1350–1359.
12.
Kawamata T, Amano K, Aihara Y, Kubo O, Hori T: Optimal treatment strategy for craniopharyngiomas based on long-term functional outcomes of recent and past treatment modalities. Neurosurg Rev Jan 2010;33:71–81.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.